DiaMedica Therapeutics Inc
$ 7.08
1.00%
21 Jul - close price
- Market Cap 377,722,000 USD
- Current Price $ 7.08
- High / Low $ 7.14 / 6.98
- Stock P/E N/A
- Book Value 0.88
- EPS -0.71
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.50 %
- ROE -0.86 %
- 52 Week High 10.42
- 52 Week Low 4.01
About
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.
Analyst Target Price
$15.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-03-30 | 2025-11-12 | 2025-08-12 | 2025-05-13 | 2025-03-17 | 2024-11-13 | 2024-08-07 | 2024-05-08 | 2024-03-19 | 2023-11-13 | 2023-08-14 |
| Reported EPS | -0.1655 | -0.17 | -0.17 | -0.18 | -0.18 | -0.18 | -0.15 | -0.13 | -0.14 | -0.14 | -0.12 | -0.16 |
| Estimated EPS | -0.1933 | -0.175 | -0.17 | -0.19 | -0.18 | -0.1725 | -0.15 | -0.16 | -0.16 | -0.14 | -0.13 | -0.18 |
| Surprise | 0.0278 | 0.005 | 0 | 0.01 | 0 | -0.0075 | 0 | 0.03 | 0.02 | 0 | 0.01 | 0.02 |
| Surprise Percentage | 14.3818% | 2.8571% | 0% | 5.2632% | 0% | -4.3478% | 0% | 18.75% | 12.5% | 0% | 7.6923% | 11.1111% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.19 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DMAC
2026-07-20 04:09:44
DiaMedica Therapeutics Inc. announced inducement grants on July 17, 2026, awarding options to purchase 160,000 shares of common stock to a newly hired non-executive employee. These options, granted as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4), have an exercise price of $7.64 per share and a ten-year term, with vesting beginning after one year. DiaMedica is a clinical-stage biopharmaceutical company focusing on treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke.
2026-07-17 20:10:45
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that it granted options to a newly hired non-executive employee to purchase 160,000 shares of common stock. The stock options, with an exercise price of $7.64 per share, were a material inducement for their employment, complying with Nasdaq Listing Rule 5635(c)(4). These options will vest over time, starting with 25% on the one-year anniversary of the grant date and the remainder in quarterly installments.
2026-07-15 07:12:23
Diamedica Therapeutics Inc. (NASDAQ: DMAC) is showing conflicting sentiment across horizons, suggesting choppy conditions. The article highlights an exceptional 79.0:1 risk-reward setup targeting a 21.9% gain versus 0.3% risk. AI models have generated three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles and holding periods, with specific entry, target, and stop-loss levels.
2026-07-08 16:12:23
The article discusses the enterprise value to revenue forward for DiaMedica Therapeutics Inc. (NASDAQ: DMAC). It highlights financial data available on TradingView, covering various aspects of the company's financial performance.
2026-07-08 02:39:32
DiaMedica Therapeutics Inc (DMAC) is currently in the "Fair zone" according to its forward PS ratio, which is 0.00 compared to a five-year average of -4.69. The company's current Price-to-Book (P/B) ratio of 9.14 is significantly higher than its 3-year and 5-year averages, and its Forward Free Cash Flow (FCF) yield is -7.20%. Compared to competitors, DMAC's P/S ratio appears unsustainable given its robust revenue growth.
2026-07-07 03:47:28
This article provides the enterprise value to EBITDA forward for DiaMedica Therapeutics Inc. (NASDAQ:DMAC). It presents financial data and company overview information sourced from TradingView, FactSet, and other financial data providers.
